Dr. Imre Kacskovics FOUNDER & CHAIRMAN
Dr. Tonio Barlage Member
Gábor Komár Member
Dr. Lee Schalop Member
Beatrice Tschanz-Kramel Member
The operations of the company are managed under the direction of the Board of Directors, within the framework set by the Swiss Companies Act and our Articles of Association as well as any complementary rules of procedure as defined by the Board, such as the Corporate Governance Guidelines and related Board Committee charters.
The Board represents and is accountable to the shareholders of the company. The Board's responsibilities are active, and include the responsibility to regularly evaluate the strategic direction of the company, management policies and the effectiveness with which management implements them. The Board's responsibilities also include overseeing the structure and composition of the company's management and monitoring legal compliance and the management of risks related to the company's operations. In doing so, the Board may set annual ranges and/or individual limits for capital expenditures, investments and divestitures and financial commitments not to be exceeded without Board approval.
Dr. Kacskovics has served as a Vice Chairman of ImmunoGenes and as the company's Chief Executive Officer since August 2008, and has served as Chairman since October 2014. Dr. Kacskovics received his DVM degree in 1987, and his PhD (immunology) in 1998 from the University of Veterinary Science, Budapest where he worked as a senior scientist until 2006. He spent his postdoctoral training at the University of Iowa from 1991 to 1994, and has been a visiting scientist at the Karolinska Institute since 1995. Since 2006, he has been an Associate Professor at the Department of Immunology, Eötvös Loránd University, Budapest. Dr. Kacskovics is an expert in immunoglobulins and Fc receptors areas and has been published in over 40 peer-reviewed publications.
Dr. Barlage has served as a director of ImmunoGenes since May 2010 and as Chief Financial Advisor since 2011.
Dr. Barlage has been Managing Partner at PolyTechnos since 2003. He adds an investment and financial analytical capability as well as an operational expertise which is truly unique.
He came to PolyTechnos as one of the most successful executives in the German Engineering field and has built the world's leading hydraulics company Sauer from its German, family-owned mid-cap beginnings to its presence on world stage and public markets. He served as President, COO, and CFO of Sauer, which he took public in 1998 (NYSE: SHS) and which merged with Danfoss Mobile Hydraulics in 2000, creating a company with more than a USD 1B market cap. Sauer is one of the world's largest manufacturers of mobile hydraulic equipment, with operations in the U.S., Europe, Eastern Europe, and Asia. Tonio created the Slovakia and China divisions.
Until 1986, he was audit division manager at Arthur Andersen in Düsseldorf, Germany. He has long standing expertise as a board member and his current appointments include DBD, Nanotron, Innolume, and Panoratio, as well as Framepool.
Dr. Barlage received his graduate degree in electrical engineering and his Ph.D. in business administration from the Technical University of Berlin. He also is a Certified Public Accountant and a Certified Tax Adviser.
Dr. Schalop is a biotech industry angel investor and entrepreneur, a role he has held since graduating with a doctor of medicine degree from the Albert Einstein College of Medicine in 2008. Prior to attending medical school, Dr. Schalop spent more than 19 years in the financial industry at a number of major Wall Street firms, including Morgan Stanley, J.P. Morgan, Credit Suisse and Banc of America Securities. From 1985 to 1993, he was an investment banker and raised billions in capital for public and private firms. From 1993 to 2004, he served as a research analyst and authored more than 1,000 reports covering more than 50 different publicly-traded companies and earned a reputation for groundbreaking research. He is also a director of Oncoceutics, Inc., a drug discovery company focused on the development of novel anti-cancer compounds, the Juvenile Diabetes Research Foundation New York Chapter, a non-profit dedicated to finding a cure for diabetes and its complications through research, and on the advisory board of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania. He is a summa cum laude graduate of the University of Pennsylvania where he earned dual degrees from the University's Wharton School and College of Arts and Sciences.
Mr. Komar has served as a director of ImmunoGenes since August 2008.
Gabor Komar is a Budapest based investor and entrepreneur. He is active in the trading, financial, aviation and biotechnology industries. Gabor is a founding investor of ImmunoGenes.
Ms. Tschanz-Kramel has served as a director of ImmunoGenes since August 2008. She studied language and history in Oxford, Barcelona and Paris. She worked for two years for Schweizer Grossbank in Brazil and Argentina. For 20 years, she worked as a Journalist for various companies. She has worked in corporate communications at Ringier AG, Jelmoli AG and Swissair. Since 2003, she has been a self-employed Communication Consultant and works for numerous non-profit organizations. From 2000 until 2008, she was a Member of the Board of Valora Holding AG and most recently served as Chairwoman of the Board. Ms. Tschanz-Kramel is Owner and Managing Director of TK Communications. She holds a Master's degree in Communication.